NCT03029338 2026-02-11
CD19 CAR T Cells in Patients With Relapsed or Refractory CD19 Positive B-cell Lymphoma
Institute of Hematology & Blood Diseases Hospital, China
Phase 1 Completed
Clinical Trials
88 trialsNCT01516580 2026-02-09
Intergroup Randomized Trial for Children or Adolescents With B-Cell Non Hodgkin Lymphoma or B-Acute Leukemia: Rituximab Evaluation in High Risk Patients
Gustave Roussy, Cancer Campus, Grand Paris
Phase 3 Completed
NCT05149391 2026-01-30
A Study of C-CAR039 in Subjects With Relapsed and/or Refractory B Cell Non-Hodgkin's Lymphoma
Peking University
Phase 1 Completed
NCT06004167 2025-12-09
Adaptive Bridging RT in R/R B-cell Lymphoma (Pre-CAR T)
Massachusetts General Hospital
Phase NA Completed
NCT05556239 2025-12-08
STAY-STRONG
Rigshospitalet, Denmark
Phase NA Completed
NCT04359784 2025-10-23
Anakinra for the Prevention of Cytokine Release Syndrome and Neurotoxicity in Patients With B-Cell Non-Hodgkin Lymphoma Receiving CD19-Targeted CAR-T Cell Therapy
Fred Hutchinson Cancer Center
Phase 2 Completed
NCT04074746 2025-09-30
Modified Immune Cells (AFM13-NK) and A Monoclonal Antibody (AFM13) in Treating Patients With Recurrent or Refractory CD30 Positive Hodgkin or Non-Hodgkin Lymphomas
M.D. Anderson Cancer Center
Phase 1/2 Completed
NCT04410900 2025-09-08
Vaccine Responsiveness After CAR-T Cell Therapy
Fred Hutchinson Cancer Center
Phase 1 Completed
NCT00498043 2025-09-03
LNH2007-3B
Hospices Civils de Lyon
Phase 2 Completed
NCT06027957 2025-08-26
CD19 CAR T-Cell Therapy for R/R Non-Hodgkin Lymphoma and Acute Lymphoblastic Leukemia
Vinmec Research Institute of Stem Cell and Gene Technology
Phase 1 Completed
NCT04088890 2025-06-10
Autologous CD22 CAR T Cells in Adults w/ Recurrent or Refractory B Cell Malignancies
Stanford University
Phase 1 Completed
NCT04317885 2025-05-23
A Study Evaluating Safety and Efficacy of C-CAR039 Treatment in NHL Subjects
Shanghai Tongji Hospital, Tongji University School of Medicine
Phase 1 Completed
NCT04655677 2025-05-23
A Study of C-CAR039 Treatment in Subjects With r/r NHL SubjectsNon-Hodgkin's Lymphoma
Peking Union Medical College Hospital
Phase 1 Completed
NCT04240808 2025-05-15
Study of Feasibility and Safety of UCD19 Chimeric Antigen Receptor (CAR) T Cells in Adult Subjects With Relapsed/Refractory (R/R) B-Cell Non-Hodgkin's Lymphoma (B-NHL)
University of Colorado, Denver
Phase 1 Completed
NCT04578600 2025-04-24
CC-486, Lenalidomide, and Obinutuzumab for the Treatment of Recurrent or Refractory CD20 Positive B-cell Lymphoma
University of California, Davis
Phase 1 Completed
NCT01701986 2025-02-28
Gemcitabine Hydrochloride, Clofarabine, and Busulfan Before Donor Stem Cell Transplant in Treating Patients With Refractory B-Cell or T-Cell Non-Hodgkin Lymphoma or Hodgkin Lymphoma
M.D. Anderson Cancer Center
Phase 1/2 Completed
NCT04136275 2024-12-12
CAR-37 T Cells in Hematologic Malignancies
Massachusetts General Hospital
Phase 1 Completed
NCT03410901 2024-12-11
TLR9 Agonist SD-101, Anti-OX40 Antibody BMS 986178, and Radiation Therapy in Treating Patients With Low-Grade B-Cell Non-Hodgkin Lymphomas
Stanford University
Phase 1 Completed
NCT00801216 2024-12-10
SCNSL1
IRCCS San Raffaele
Phase 2 Completed
NCT04450069 2024-08-20
CLBR001 and SWI019 in Patients With Relapsed / Refractory B-cell Malignancies
Calibr, a division of Scripps Research
Phase 1 Completed
NCT04605666 2024-08-20
CD19-CAR-T2 Cells for CD19 Positive B Cell Malignancies
Nanfang Hospital, Southern Medical University
Phase 2 Completed
NCT05510596 2024-08-09
MR-ICANS
University Hospital, Montpellier
Phase NA Completed
NCT04036019 2024-05-28
A Study of C-CAR066 in Subjects With r/r B Cell Lymphoma Who Received CD19 CAR-T Therapy
Shanghai Tongji Hospital, Tongji University School of Medicine
Phase 1 Completed
NCT02981914 2024-04-22
Pilot Study of Pembrolizumab Treatment for Disease Relapse After Allogeneic Stem Cell Transplantation
University of Chicago
Phase EARLY_PHASE1 Completed
NCT03458546 2024-02-21
Study of Roflumilast in Combination With Standard Chemotherapy for High-risk Diffuse Large B-cell Lymphoma
The University of Texas Health Science Center at San Antonio
Phase 1 Completed
NCT02332980 2024-01-03
Pembrolizumab Alone or With Idelalisib or Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Other Low-Grade B-Cell Non-Hodgkin Lymphomas
Mayo Clinic
Phase 2 Completed
NCT00968760 2023-12-19
CD19-specific T Cell Infusion in Patients With B-Lineage Lymphoid Malignancies
M.D. Anderson Cancer Center
Phase 1 Completed
NCT03349450 2023-11-02
SPiReL
Sunnybrook Health Sciences Centre
Phase 2 Completed
NCT02661035 2023-09-21
Allo HSCT Using RIC for Hematological Diseases
Masonic Cancer Center, University of Minnesota
Phase 2 Completed
NCT03019055 2023-07-27
Study of CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell
Medical College of Wisconsin
Phase 1 Completed
NCT04748185 2023-07-10
Immunogenicity and Safety of Commercially Available Vaccines Against SARS-CoV-2 (COVID-19) in Patients With Hematologic Malignancies
Mayo Clinic
Completed
NCT03003546 2023-06-15
Nab-paclitaxel/Rituximab-coated Nanoparticle AR160 in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma, LS1681 Trial
Mayo Clinic
Phase 1 Completed
NCT04121507 2023-05-24
ASTRAL- a Clinical Study to Assess the Efficacy and Toxicity of High-dose Chemotherapy
GWT-TUD GmbH
Phase 2 Completed
NCT01238692 2023-03-24
A Phase II Study of Oral Panobinostat (LBH589) and Rituximab to Treat Diffuse Large B Cell Lymphoma (DLBCL)
Jewish General Hospital
Phase 2 Completed
NCT02300402 2023-03-20
ADAMANTIUS
The Lymphoma Academic Research Organisation
Completed
NCT04158128 2023-01-18
The Clinical Implications of Immune Checkpoint Pathways in PCNSL
National Taiwan University Hospital
Completed
NCT00849147 2023-01-04
Bone Marrow Transplant From Partially Matched Donors and Nonmyeloablative Conditioning for Blood Cancers (BMT CTN 0603)
Medical College of Wisconsin
Phase 2 Completed
NCT01141712 2023-01-04
Autologous Transplant in HIV Patients (BMT CTN 0803)
Medical College of Wisconsin
Phase 2 Completed
NCT02955823 2022-12-23
A Phase II Study of the FIL on Elderly Frail Patients With DLBCL
Fondazione Italiana Linfomi - ETS
Phase 2 Completed
NCT00864227 2022-12-14
Evaluating the Safety and Effectiveness of an Umbilical Cord Blood Stem Cell Transplant (BMT CTN 0604)
Medical College of Wisconsin
Phase 2 Completed
NCT02049541 2022-06-30
Study of BKM120 & Rituximab in Patients With Relapsed or Refractory Indolent B-Cell Lymphoma
Ohio State University Comprehensive Cancer Center
Phase 1 Completed
NCT02741388 2021-12-07
SELINDA
The Lymphoma Academic Research Organisation
Phase 1 Completed
NCT05133505 2021-11-24
Characterisation of TIM-3/Gal-9 Immune Checkpoints in Primary Central Nervous System Diffuse Large B Cell Lymphomas
University Hospital, Montpellier
Completed
NCT01665768 2021-10-26
Maintenance Rituximab With mTor Inhibition After High-dose Consolidative Therapy in Lymphoma
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Completed
NCT03068416 2021-10-20
CD19-targeting, 3rd Generation CAR T Cells for Refractory B Cells Malignancy
Uppsala University
Phase 2 Completed
NCT02933320 2021-07-08
BI-1206 and an Anti-CD20 Antibody in Patients With CD32b Positive B-cell Lymphoma or Leukaemia
Cancer Research UK
Phase 1/2 Completed
NCT02424968 2021-06-24
CD8+ Memory T-Cells as Consolidative Therapy After Donor Non-myeloablative Hematopoietic Cell Transplant in Treating Patients With Leukemia or Lymphoma
Stanford University
Phase 2 Completed
NCT01613300 2021-05-26
Study of OFATUMUMAB as Part of the Scheme of Reduced Intensity Conditioning in High Risk Non-Hodgkin Lymphoma B Patients
Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea
Phase 2 Completed
NCT01921387 2020-08-04
Radiolabeled Monoclonal Antibody and Combination Chemotherapy Before Stem Cell Transplant in Treating Patients With High-Risk Lymphoid Malignancies
Fred Hutchinson Cancer Center
Phase 1/2 Completed
NCT01626495 2020-03-23
Pedi CART19
University of Pennsylvania
Phase 1/2 Completed